1. Home
  2. BETR vs ABOS Comparison

BETR vs ABOS Comparison

Compare BETR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Better Home & Finance Holding Company

BETR

Better Home & Finance Holding Company

N/A

Current Price

$15.27

Market Cap

204.6M

Sector

Finance

ML Signal

N/A

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

N/A

Current Price

$0.21

Market Cap

165.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BETR
ABOS
Founded
2014
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
204.6M
165.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BETR
ABOS
Price
$15.27
$0.21
Analyst Decision
Buy
Hold
Analyst Count
8
6
Target Price
★ $24.00
$1.00
AVG Volume (30 Days)
849.4K
★ 5.5M
Earning Date
11-09-2026
10-26-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 20.88
N/A
EPS
N/A
★ N/A
Revenue
★ $164,872,000.00
N/A
Revenue This Year
$13.39
N/A
Revenue Next Year
$23.31
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 51.97
N/A
52 Week Low
$7.51
$0.19
52 Week High
$55.75
$3.60

Technical Indicators

Market Signals
Indicator
BETR
ABOS
Relative Strength Index (RSI) 45.92 21.00
Support Level $10.45 $0.19
Resistance Level $31.07 $2.56
Average True Range (ATR) 2.39 0.08
MACD -0.68 -0.05
Stochastic Oscillator 3.48 0.66

Price Performance

Historical Comparison
BETR
ABOS

About BETR Better Home & Finance Holding Company

Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: